Prime Medicine (PRME) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Chardan Capital | Maintained | Buy | $7.00 | Sep 25, 2026 |
| Chardan Capital | Maintained | Buy | $7.00 | Aug 25, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $9.00 | Aug 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 | Aug 10, 2026 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $8.00 | Jun 29, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $11.00 | Mar 12, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $6.00 | Dec 23, 2025 |
| Citigroup | Maintained | Neutral | $4.25 from $5.00 | Nov 11, 2025 |
| Chardan Capital | Maintained | Buy | $9.00 from $10.00 | Nov 10, 2025 |
| Chardan Capital | Maintained | Buy | $10.00 from $12.00 | Aug 8, 2025 |
| Citigroup | Downgraded | Buy → Neutral | $1.50 from $10.00 | May 27, 2025 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | May 20, 2025 |
| JP Morgan | Downgraded | Overweight → Neutral | — | May 20, 2025 |
| JMP Securities | Maintained | Market Outperform | $6.00 from $10.00 | May 20, 2025 |
| Chardan Capital | Maintained | Buy | $12.00 from $16.00 | May 19, 2025 |
| Chardan Capital | Maintained | Buy | $16.00 from $15.00 | Mar 20, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Mar 19, 2025 |
| Citizens Capital Markets | Maintained | Market Outperform | $10.00 | Mar 4, 2025 |
| Chardan Capital | Maintained | Buy | $15.00 | Mar 3, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Mar 3, 2025 |
Frequently asked questions
What is the price target for PRME stock?
The average 12-month analyst price target for Prime Medicine (PRME) is $8.00, with a high estimate of $9.00 and a low of $7.00, across 3 analysts.
Is PRME a buy, sell, or hold?
Analysts covering Prime Medicine currently average a Buy rating: 10 buy, 3 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for PRME?
The average price target of $8.00 implies 130.22% upside from the last price of $3.48.
What is the latest analyst rating on PRME?
On Sep 25, 2026, Chardan Capital maintained Prime Medicine at Buy with a price target of $7.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.